Understanding how certain proteins help control gene activity and maintain DNA stability
Official title: Regulation of transcription termination by checkpoint kinases Mec1p and Rad53p
Funded at St. John's University · NIH-10729762 · Data updated 2026-11-12
This study is looking at how certain proteins help control the end of gene reading in our cells, especially when there's DNA damage or stress, to keep our genes stable and healthy, which could help us understand more about cancer and improve treatments for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $492,000 |
| NIH project number | 1R15GM151681-01 |
| Project ID | NIH-10729762 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers that may be influenced by DNA damage and repair mechanisms.
✕Less likely to help
Patients with non-malignant conditions or those whose cancers are not related to DNA damage responses may not benefit from this research.
What this research studies
This research investigates the role of checkpoint kinases Mec1p and Rad53p in regulating the process of transcription termination, which is crucial for maintaining genome stability. By examining how these proteins respond to DNA damage and replication stress, the study aims to uncover mechanisms that prevent interference between transcription and DNA replication. The approach involves analyzing the behavior of RNA polymerase II at gene ends and how its accumulation can lead to genomic instability when checkpoint functions are compromised. Patients may benefit from insights gained into how these processes affect cancer development and treatment.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving cancer treatments by enhancing our understanding of DNA damage responses.
How similar studies have gone: Other research has shown promising results in understanding DNA damage responses, indicating that this approach has potential for significant findings.
Where this research is happening
-
St. John's University
Queens, United States Active
Researchers
- Principal investigator: Vancura, Ales — St. John's University
- Study coordinator: Vancura, Ales
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to how proton channels in cells open, close, and move protons in cancer and surrounding tissues
A scientist at ST. JOHN'S UNIVERSITY is studying how proton channels (Otop family) work at the molecular level and how their behavior affects cancer and related conditions.
-
Biocontained whole-cell biosensors to detect dysbiosis and inflammation
A scientist team is creating safe, engineered bacteria that can sit in saliva and signal early signs of imbalance in the microbiome and inflammation, potentially helping with early diagnosis.
-
New highly selective PARP1 inhibitors for brain cancers and beyond
A new class of PARP1 inhibitors is being developed to treat cancers with BRCA defects by targeting PARP1 more selectively and avoiding brain toxicity and drug resistance.
-
Iron and ferroptosis: how iron metabolism shapes a cell’s self-destruction in cancer
A researcher at ST. John’s University is testing how iron in cancer cells affects ferroptosis, a unique form of cell death, to find new ways to influence tumor behavior.
-
MG53 and GsdmD interaction to protect heart cells after a heart attack
A study to see if MG53 can team up with GsdmD to reduce inflammatory cell death and limit heart damage after a heart attack.
-
16α-hydroxylated bile acids and how they control energy intake and liver fat
A study to understand how a specific form of bile acid (with a 16α hydroxyl group) influences how much people eat and how fat is processed in the liver, using cells and animal models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.